Drugs / VLA1601
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06334393 | Mar 2024 → Apr 2025 | Zika virus infectious disease | Valneva Austria GmbH | Completed | No outcome recorded |
| Phase 1 | NCT03425149 | Feb → Jun 2018 | Zika virus infectious disease | Valneva Austria GmbH | Completed | Met primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Valneva Austria GmbH | Results Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate valneva.com ↗ |
| 2019-08-01 | Valneva Austria GmbH | Results Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress valneva.com ↗
The final results confirmed the interim Phase 1 data reported by Valneva and Emergent Biosolutions at the end of 2018. |
| 2018-11-19 | Valneva Austria GmbH | Results Emergent Biosolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus valneva.com ↗
Emergent BioSolutions Inc. (NYSE: EBS) and Valneva SE (VLA) today announced positive interim results for the Phase 1 study evaluating VLA1601, their vaccine candidate against the Zika virus. |
| 2018-11-19 | Emergent BioSolutions | Results Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus emergentbiosolutions.com ↗ |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Valneva Austria GmbH | Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate valneva.com ↗ |
| 2019-08-01 | Valneva Austria GmbH | Valneva Reports H1 2019 Results Marked by Strong Operational Performance and Major Corporate Progress valneva.com ↗ |
| 2018-11-19 | Valneva Austria GmbH | Emergent Biosolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus valneva.com ↗ |
| 2018-11-19 | Emergent BioSolutions | Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus emergentbiosolutions.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VLA1601 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03425149 ↗ |
| Modality | Vaccine | “inactivated, whole Zika virus (ZIKV) vaccine candidate” NCT03425149 ↗ |
| Route | Intramuscular | “Each dose will be administered intramuscularly (i.m.)” NCT03425149 ↗ |